Insider Selling: iRadimed (NASDAQ:IRMD) CEO Sells 2,500 Shares of Stock

iRadimed Corporation (NASDAQ:IRMD) CEO Roger Susi sold 2,500 shares of the business’s stock in a transaction on Tuesday, March 10th. The shares were sold at an average price of $100.11, for a total transaction of $250,275.00. Following the sale, the chief executive officer owned 2,247,500 shares of the company’s stock, valued at $224,997,225. This trade represents a 0.11% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through this link.

iRadimed Stock Performance

Shares of iRadimed stock traded down $1.23 during trading hours on Tuesday, reaching $98.95. The company’s stock had a trading volume of 55,132 shares, compared to its average volume of 72,170. The company has a market capitalization of $1.26 billion, a P/E ratio of 56.54 and a beta of 1.12. The stock’s fifty day simple moving average is $100.06 and its two-hundred day simple moving average is $87.98. iRadimed Corporation has a one year low of $47.48 and a one year high of $107.90.

iRadimed (NASDAQ:IRMD) last posted its earnings results on Tuesday, February 10th. The medical equipment provider reported $0.54 earnings per share for the quarter, topping analysts’ consensus estimates of $0.49 by $0.05. iRadimed had a net margin of 26.82% and a return on equity of 23.85%. The company had revenue of $22.69 million for the quarter, compared to analyst estimates of $21.60 million. iRadimed has set its Q1 2026 guidance at 0.440-0.480 EPS and its FY 2026 guidance at 2.060-2.210 EPS. As a group, research analysts forecast that iRadimed Corporation will post 1.66 earnings per share for the current year.

iRadimed Increases Dividend

The business also recently announced a quarterly dividend, which was paid on Friday, March 6th. Stockholders of record on Monday, February 23rd were issued a $0.20 dividend. This is a boost from iRadimed’s previous quarterly dividend of $0.17. This represents a $0.80 dividend on an annualized basis and a dividend yield of 0.8%. The ex-dividend date was Monday, February 23rd. iRadimed’s dividend payout ratio is 45.71%.

Analysts Set New Price Targets

A number of research firms recently commented on IRMD. Roth Mkm reissued a “buy” rating and issued a $120.00 price target on shares of iRadimed in a research report on Tuesday, February 10th. Lake Street Capital reiterated a “buy” rating and issued a $120.00 target price on shares of iRadimed in a report on Wednesday, February 11th. Finally, Weiss Ratings restated a “buy (b-)” rating on shares of iRadimed in a report on Monday, December 29th. Three equities research analysts have rated the stock with a Buy rating and one has given a Hold rating to the company’s stock. Based on data from MarketBeat, iRadimed has an average rating of “Moderate Buy” and a consensus price target of $120.00.

Institutional Inflows and Outflows

A number of institutional investors have recently bought and sold shares of the business. CWM LLC lifted its stake in shares of iRadimed by 19.5% during the 4th quarter. CWM LLC now owns 657 shares of the medical equipment provider’s stock valued at $64,000 after buying an additional 107 shares in the last quarter. Johnson Investment Counsel Inc. grew its stake in iRadimed by 0.7% in the 3rd quarter. Johnson Investment Counsel Inc. now owns 25,842 shares of the medical equipment provider’s stock valued at $1,839,000 after buying an additional 187 shares in the last quarter. Summit Global Investments raised its holdings in iRadimed by 2.7% during the 3rd quarter. Summit Global Investments now owns 7,139 shares of the medical equipment provider’s stock valued at $508,000 after acquiring an additional 188 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its position in shares of iRadimed by 5.1% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 4,811 shares of the medical equipment provider’s stock worth $252,000 after acquiring an additional 234 shares in the last quarter. Finally, Zurcher Kantonalbank Zurich Cantonalbank boosted its holdings in shares of iRadimed by 4.8% in the fourth quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 5,824 shares of the medical equipment provider’s stock worth $567,000 after acquiring an additional 267 shares during the period. Institutional investors own 92.34% of the company’s stock.

iRadimed Company Profile

iRadimed Corporation designs, develops and manufactures medical device solutions for MRI environments. The company’s core product line consists of MRI-compatible infusion systems engineered to deliver precise fluid management during magnetic resonance imaging procedures. These devices are crafted to minimize electrical noise and interference, ensuring both patient safety and image clarity in diagnostic and interventional settings.

In addition to infusion pumps, iRadimed offers a range of complementary accessories and monitoring solutions tailored to MRI suites.